Search ORGO
Organogenesis Holdings Inc.
Nasdaq · CIK 1661181
Last close1.33
Daily change-0.07 (-5.00%)
10 Years gain-86.36%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ORGO · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
35.9Momentum
0.0Acceleration
0.0Confidence
82.0Annual Revenue10
Quarterly Revenue37
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth9.3 / 25
Quality9.8 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 6.4911 percentage points.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 24.9162 percentage points.
Key Metrics
Revenue Growth TTM-24.71%OK
Revenue CAGR 3Y7.76%OK
Gross Margin100%OK
Operating Margin-33.57%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-75.09%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1.88%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $564.17M | $564.17M | $44.69M | -$10.31M | -$24.46M | 100% | 7.92% | -4.34% | 21.11% | 130.25M |
| 2025 FY Dec 31, 2024 | $482.04M | $482.04M | -$1.28M | $14.21M | $4.18M | 100% | -0.27% | 0.87% | n/a | 131.67M |
| 2025 FY Dec 31, 2023 | $433.14M | $433.14M | $12.53M | $30.92M | $6.55M | 100% | 2.89% | 1.51% | n/a | 132.75M |
| 2024 FY Dec 31, 2022 | $450.89M | $345.87M | $22.30M | $24.86M | -$9.04M | 76.71% | 4.95% | -2% | 7.84% | 132.38M |
| 2023 FY Dec 31, 2021 | $467.36M | $353.16M | $72.22M | $61.98M | $30.76M | 75.57% | 15.45% | 6.58% | 28.55% | 133.66M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $332.85M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-338049, 0001193125-25-269697 |
| Revenue Growth TTM | -24.71% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-338049, 0001193125-25-269697 |
| Revenue CAGR 3Y | 7.76% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076730 |
| Revenue CAGR 5Y | 10.77% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-076730 |
| Gross Profit CAGR 3Y | 17.71% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076730 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-338049, 0001193125-25-269697 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-338049, 0001193125-25-269697 |
| Operating Margin | -33.57% | Operating Income / Revenue | OK | 0001193125-26-338049, 0001193125-25-269697 |
| ROIC | -75.09% | NOPAT / Average Invested Capital | OK | 0001193125-26-338049, 0001193125-25-269697 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-338049 |
| Current Ratio | 3.52x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.59 | Revenue / Diluted Shares | OK | 0001193125-26-338049, 0001193125-25-269697 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |